Novakand Pharma
0.11 SEK
0.00 %
Less than 1K followers
NOVKAN
First North Stockholm
Biotechnology & Pharmaceuticals
Health Care
Overview
Financials & Estimates
Ownership
Dividend
Investor consensus
0.00 %
-4.55 %
-30.31 %
-39.17 %
-88.28 %
-89.58 %
-96.71 %
-99.26 %
-99.69 %
Novakand Pharma is a pharmaceutical company. The company develops drugs that counteract damage caused by acute and chronic inflammation. The products are mainly developed to counteract hyperinflammation in various disease states and thereby protect vital organs, for example in connection with heart attacks and severe viral infections. Novakand Pharma is planning two clinical phase II studies, in COVID-19 and in heart patients. The company conducts research and development at Karolinska Institutet Science Park in Stockholm.
Read moreMarket cap
13.21M SEK
Turnover
40.16K SEK
Revenue
-
EBIT %
-
P/E
-
Dividend yield-%
-
Revenue and EBIT-%
Revenue K
EBIT-% (adj.)
EPS and dividend
EPS (adj.)
Dividend %
Financial calendar
22/5
2026
Interim report Q1'26
25/5
2026
General meeting '26
28/8
2026
Interim report Q2'26
All
Webcasts
Press releases
ShowingAll content types
Novakand’s Board of Directors proposes new business direction and relisting to be presented at Extraordinary General Meeting
Novakand Pharma informerar aktieägarna om att den extra bolagsstämman den 12 mars 2026 ställs in
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools